CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan
- 31 October 2006
- journal article
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 103 (1), 212-218
- https://doi.org/10.1016/j.ygyno.2006.02.026
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Should CA-125 Response Criteria Be Preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for Prognostication During Second-Line Chemotherapy of Ovarian Carcinoma?Journal of Clinical Oncology, 2004
- Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian CancerClinical Cancer Research, 2004
- Use of CA-125 to Assess Response to New Agents in Ovarian Cancer TrialsJournal of Clinical Oncology, 2003
- Positron Emission Tomography/Computed Tomography Imaging for the Detection of Recurrent Ovarian and Fallopian Tube Carcinoma: A Retrospective ReviewGynecologic Oncology, 2002
- The Clinical Utility of Liposomal Doxorubicin in Recurrent Ovarian CancerGynecologic Oncology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group studyAnnals Of Oncology, 1996
- Tumor markers in the management of patients with ovarian cancerCancer Treatment Reviews, 1995
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983